Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Tuberculosis

  Free Subscription


Articles published in Eur Respir J

Retrieve available abstracts of 253 articles:
HTML format



Single Articles


    April 2021
  1. VINEY K, Linh NN, Gegia M, Zignol M, et al
    New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization.
    Eur Respir J. 2021;57.
    PubMed    


  2. SRIVASTAVA S, Gumbo T
    Therapeutic drug monitoring and fluoroquinolones for multidrug-resistant tuberculosis.
    Eur Respir J. 2021;57.
    PubMed    


  3. MAITRE T, Guglielmetti L, Veziris N
    Defining optimal fluoroquinolone exposure against Mycobacterium tuberculosis: contribution of murine studies.
    Eur Respir J. 2021;57.
    PubMed    


    March 2021
  4. BOHLBRO AS, Hvingelby VS, Rudolf F, Wejse C, et al
    Active case-finding of tuberculosis in general populations and at-risk groups: a systematic review and meta-analysis.
    Eur Respir J. 2021 Mar 25. pii: 13993003.00090-2021.
    PubMed     Abstract available


  5. GUPTA RK, Lule SA, Krutikov M, Gosce L, et al
    Screening for tuberculosis among high-risk groups attending London Emergency Departments: A prospective observational study.
    Eur Respir J. 2021 Mar 18. pii: 13993003.03831-2020.
    PubMed    


  6. DE VRIES G, Gainaru D, Keizer S, Mahler B, et al
    Human reading versus computer automated reading of chest X-rays in a tuberculosis screening programme in Romania.
    Eur Respir J. 2021 Mar 10. pii: 13993003.04628-2020.
    PubMed    


    February 2021
  7. HEYCKENDORF J, Marwitz S, Reimann M, Avsar K, et al
    Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model.
    Eur Respir J. 2021 Feb 11. pii: 13993003.03492-2020.
    PubMed     Abstract available


  8. ZHANG N, Savic RM, Boeree MJ, Peloquin C, et al
    Optimising pyrazinamide for the treatment of tuberculosis.
    Eur Respir J. 2021 Feb 4. pii: 13993003.02013-2020.
    PubMed     Abstract available


    January 2021
  9. HAMADA Y, den Boon S, Maria Cirillo D, Penn-Nicholson A, et al
    Framework for the evaluation of new tests for tuberculosis infection.
    Eur Respir J. 2021 Jan 21. pii: 13993003.04078-2020.
    PubMed     Abstract available


    December 2020
  10. CHESOV D, Heyckendorf J, Alexandru S, Donica A, et al
    Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country.
    Eur Respir J. 2020 Dec 17. pii: 13993003.02544-2020.
    PubMed     Abstract available


    November 2020
  11. MIRZAYEV F, Viney K, Linh NN, Gonzalez-Angulo L, et al
    World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update.
    Eur Respir J. 2020 Nov 26. pii: 13993003.03300-2020.
    PubMed     Abstract available


  12. NIKOLAYEVSKYY V, Holicka Y, van Soolingen D, van der Werf MJ, et al
    Impact of COVID-19 pandemic on tuberculosis laboratory services in Europe.
    Eur Respir J. 2020 Nov 12. pii: 13993003.03890-2020.
    PubMed    


  13. DAVIES FORSMAN L, Niward K, Kuhlin J, Zheng X, et al
    Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China.
    Eur Respir J. 2020 Nov 5. pii: 13993003.03463-2020.
    PubMed    


  14. GEBRESELASSIE N, Kasaeva T, Zignol M
    A global strategy for tuberculosis research and innovation.
    Eur Respir J. 2020;56.
    PubMed    


    October 2020
  15. MANDALAKAS AM, Hesseling AC, Kay A, Du Preez K, et al
    Tuberculosis prevention in children: A prospective community based study in South Africa.
    Eur Respir J. 2020 Oct 29. pii: 13993003.03028-2020.
    PubMed     Abstract available


  16. GUPTA N, Ish P, Gupta A, Malhotra N, et al
    A profile of a retrospective cohort of 22 patients of COVID-19 with active/treated tuberculosis.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03408-2020.
    PubMed    


  17. KWON YS, Jeon D, Kang H, Yim JJ, et al
    Concurrent Use of Bedaquiline and Delamanid for the Treatment of Fluoroquinolone-resistant Multidrug-resistant Tuberculosis: A Nationwide Cohort Study in South Korea.
    Eur Respir J. 2020 Oct 22. pii: 13993003.03026-2020.
    PubMed    


    September 2020
  18. CHIANG CY, Islam T, Xu C, Chinnayah T, et al
    The impact of COVID-19 and the restoration of tuberculosis services in the Western Pacific Region (revised).
    Eur Respir J. 2020 Sep 25. pii: 13993003.03054-2020.
    PubMed    


  19. ALFFENAAR JC, Tiberi S, Cirillo DM, Migliori GB, et al
    Intermittent regimens for tuberculosis treatment: Back to the Future?
    Eur Respir J. 2020;56.
    PubMed    


    August 2020
  20. OHD JN, Hergens MP, Luksha Y, Buxbaum C, et al
    Evaluation of the latent tuberculosis screening and treatment strategy for asylum seekers in Stockholm, Sweden 2015-2018 - a record linkage study of the care cascade.
    Eur Respir J. 2020 Aug 27. pii: 13993003.02255-2020.
    PubMed     Abstract available


  21. MCQUAID CF, Cohen T, Dean AS, Houben RMGJ, et al
    Ongoing challenges to understanding multidrug and rifampicin-resistant tuberculosis in children versus adults.
    Eur Respir J. 2020 Aug 27. pii: 13993003.02504-2020.
    PubMed     Abstract available


  22. KIM HY, Ulbricht E, Ahn YK, Gillooly IS, et al
    Therapeutic drug monitoring practice in patients with active tuberculosis; assessment of opportunities.
    Eur Respir J. 2020 Aug 18. pii: 13993003.02349-2020.
    PubMed    


  23. FEUERRIEGEL S, Kohl TA, Utpatel C, Andres S, et al
    Rapid genomic first- and second-line drug resistance prediction from clinical Mycobacterium tuberculosis specimens using Deeplex(R)-MycTB.
    Eur Respir J. 2020 Aug 6. pii: 13993003.01796-2020.
    PubMed    


  24. KHURANA AK, Aggarwal D
    The (in)significance of TB and COVID-19 co-infection.
    Eur Respir J. 2020;56.
    PubMed    


    July 2020
  25. TAGLIANI E, Anthony R, Kohl TA, de Neeling A, et al
    Use of a Whole Genome Sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017-2019: an ECDC pilot study.
    Eur Respir J. 2020 Jul 30. pii: 13993003.02272-2020.
    PubMed     Abstract available


  26. CHEN H, Zhang K
    Insight into impact of COVID-19 epidemic on tuberculosis burden in China.
    Eur Respir J. 2020 Jul 30. pii: 13993003.02710-2020.
    PubMed    


  27. MAGRO P, Formenti B, Marchese V, Gulletta M, et al
    Impact of the SARS Coronavirus 2 epidemic on tuberculosis treatment outcome, Northern Italy.
    Eur Respir J. 2020 Jul 23. pii: 13993003.02665-2020.
    PubMed    


  28. HACKER B, Schonfeld N, Krieger D, Otto-Knapp R, et al
    Long-term safety and tolerability of delamanid-containing regimens in MDR- and XDR-TB patients in a specialised tuberculosis treatment center in Berlin, Germany.
    Eur Respir J. 2020 Jul 6. pii: 13993003.00009-2020.
    PubMed    


  29. AVALIANI Z, Gozalov O, Kuchukhidze G, Skrahina A, et al
    What is behind programmatic treatment outcome definitions for tuberculosis?
    Eur Respir J. 2020;56.
    PubMed    


  30. MOHR-HOLLAND E, Reuter A, Hughes J, Daniels J, et al
    Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa".
    Eur Respir J. 2020;56.
    PubMed    


    June 2020
  31. LAU A, Sligl W, Sun K, Barrie J, et al
    Incidence and Significance of Venous Thromboembolism in Critically ill Pulmonary Tuberculosis Patients.
    Eur Respir J. 2020 Jun 25. pii: 13993003.01753-2020.
    PubMed    


  32. TADOLINI M, Garcia-Garcia JM, Blanc FX, Borisov S, et al
    On Tuberculosis and COVID-19 co-infection.
    Eur Respir J. 2020 Jun 25. pii: 13993003.02328-2020.
    PubMed    


  33. MIN ONG CW, Migliori GB, Raviglione M, MacGregor-Skinner G, et al
    Epidemic and pandemic viral infections: impact on tuberculosis and the lung. A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN) and members(#) of ESCMID Study Group for
    Eur Respir J. 2020 Jun 25. pii: 13993003.01727-2020.
    PubMed     Abstract available


  34. KWAK N, Winters N, Campbell JR, Chan ED, et al
    Changes in treatment for multidrug-resistant tuberculosis according to national income.
    Eur Respir J. 2020 Jun 25. pii: 13993003.01394-2020.
    PubMed     Abstract available


  35. MCQUAID CF, McCreesh N, Read JM, Sumner T, et al
    The potential impact of COVID-19-related disruption on tuberculosis burden.
    Eur Respir J. 2020 Jun 8. pii: 13993003.01718-2020.
    PubMed    


  36. VISCA D, Tiberi S, Pontali E, Spanevello A, et al
    Tuberculosis in the time of COVID-19: quality of life and digital innovation.
    Eur Respir J. 2020 Jun 8. pii: 13993003.01998-2020.
    PubMed    


  37. STOCHINO C, Villa S, Zucchi P, Parravicini P, et al
    Clinical characteristics of COVID-19 and active tuberculosis co-infection in an Italian reference hospital.
    Eur Respir J. 2020 Jun 1. pii: 13993003.01708-2020.
    PubMed    


  38. CHIANG CY, Trebucq A, Piubello A, Rieder HL, et al
    The looming threat of bedaquiline resistance in tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


    May 2020
  39. GAFAR F, Ochi T, Van't Boveneind-Vrubleuskaya N, Akkerman OW, et al
    Towards elimination of childhood and adolescent tuberculosis in the Netherlands: an epidemiological time-series analysis of national surveillance data.
    Eur Respir J. 2020 May 29. pii: 13993003.01086-2020.
    PubMed     Abstract available


  40. NDJEKA N, Conradie F, Meintjes G, Reuter A, et al
    Responding to SARS-CoV-2 in South Africa: What can we learn from drug-resistant tuberculosis?
    Eur Respir J. 2020 May 29. pii: 13993003.01369-2020.
    PubMed    


  41. TADOLINI M, Codecasa LR, Garcia-Garcia JM, Blanc FX, et al
    Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
    Eur Respir J. 2020 May 26. pii: 13993003.01398-2020.
    PubMed    


  42. SAUNDERS MJ, Evans CA
    COVID-19, tuberculosis, and poverty: preventing a perfect storm.
    Eur Respir J. 2020 May 22. pii: 13993003.01348-2020.
    PubMed    


  43. HARAKA F, Schumacher SG, Ross A, Mantsoki A, et al
    Effect of history of tuberculosis on specificity of Xpert MTB/RIF.
    Eur Respir J. 2020 May 13. pii: 13993003.00343-2020.
    PubMed    


  44. VAN DEN ELSEN SHJ, Akkerman OW, Wessels M, Jongedijk EM, et al
    Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid.
    Eur Respir J. 2020 May 12. pii: 13993003.00803-2020.
    PubMed    


  45. DATTA S, Gilman RH, Montoya R, Quevedo Cruz L, et al
    Quality of life, tuberculosis and treatment outcome; a case-control and nested cohort study.
    Eur Respir J. 2020 May 4. pii: 13993003.00495-2019.
    PubMed     Abstract available


  46. WONG YJ, Lee SWH
    We must screen refugees to ensure no one is left behind: a case study of Malaysia.
    Eur Respir J. 2020;55.
    PubMed    


  47. VAN DEN ELSEN SHJ, Akkerman OW, Jongedijk EM, Wessels M, et al
    Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin.
    Eur Respir J. 2020;55.
    PubMed    


    April 2020
  48. BASU ROY R, Thee S, Blazquez-Gamero D, Falcon-Neyra L, et al
    Performance of immune-based and microbiological tests in children with TB meningitis in Europe - a multi-center Paediatric Tuberculosis Network European Trials Group (ptbnet) study.
    Eur Respir J. 2020 Apr 16. pii: 13993003.02004-2019.
    PubMed     Abstract available


  49. BASHAM CA, Cook VJ, Johnston JC
    Towards a "fourth 90": A population-based analysis of post-tuberculosis pulmonary function testing in British Columbia, Canada, 1985-2015.
    Eur Respir J. 2020 Apr 7. pii: 13993003.00384-2020.
    PubMed    


  50. SPRUIJT I, Erkens C, van den Hof S, Cobelens F, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.
    Eur Respir J. 2020;55.
    PubMed    


  51. VILLA S, Codecasa LR, Faccini M, Pontello MM, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed-methods study.
    Eur Respir J. 2020;55.
    PubMed    


  52. ALAGNA R, Besozzi G, Codecasa LR, Gori A, et al
    Celebrating World Tuberculosis Day at the time of COVID-19.
    Eur Respir J. 2020;55.
    PubMed    


    March 2020
  53. FALZON D, Schunemann HJ, Zignol M, Mirzayev F, et al
    WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence.
    Eur Respir J. 2020;55.
    PubMed    


  54. GUGLIELMETTI L, Huerga H, Khan U, Varaine F, et al
    WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion?
    Eur Respir J. 2020;55.
    PubMed    


  55. CEGIELSKI JP, Nahid P, Sotgiu G
    The continued hunt for the elusive standard short regimen for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


  56. GEBRESELASSIE N, Hutubessy R, Vekemans J, den Boon S, et al
    The case for assessing the full value of new tuberculosis vaccines.
    Eur Respir J. 2020;55.
    PubMed    


  57. FIEBIG L, Beyene N, Burny R, Fast CD, et al
    From pests to tests: training rats to diagnose tuberculosis.
    Eur Respir J. 2020;55.
    PubMed    


  58. HAMADA Y, Figueroa C, Martin-Sanchez M, Falzon D, et al
    The safety of isoniazid tuberculosis preventive treatment in pregnant and postpartum women: systematic review and meta-analysis.
    Eur Respir J. 2020;55.
    PubMed     Abstract available


    February 2020
  59. NIMMO C, Millard J, Brien K, Moodley S, et al
    Bedaquiline resistance in drug-resistant tuberculosis HIV co-infected patients.
    Eur Respir J. 2020 Feb 14. pii: 13993003.02383-2019.
    PubMed    


    January 2020
  60. RONALD LA, FitzGerald JM, Bartlett-Esquilant G, Schwartzman K, et al
    Treatment with Isoniazid or Rifampin for Latent Tuberculosis Infection: Population-Based Study of Hepatotoxicity, Completion, and Costs.
    Eur Respir J. 2020 Jan 24. pii: 13993003.02048-2019.
    PubMed     Abstract available


  61. FROBERG G, Jansson L, Nyberg K, Obasi B, et al
    Screening and treatment of tuberculosis among pregnant women in Stockholm 2016-2017.
    Eur Respir J. 2020 Jan 16. pii: 13993003.00851-2019.
    PubMed     Abstract available


    December 2019
  62. JONSSON J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J, et al
    Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden.
    Eur Respir J. 2019 Dec 20. pii: 13993003.01886-2019.
    PubMed     Abstract available


  63. DE VRIES G, Commandeur S, Erkens C, Haddad W, et al
    Towards selective tuberculosis screening of people in prison in a low-incidence country.
    Eur Respir J. 2019 Dec 20. pii: 13993003.02209-2019.
    PubMed    


  64. STEK C, Allwood B, Du Bruyn E, Buyze J, et al
    The effect of HIV-associated tuberculosis, tuberculosis-IRIS, and prednisone on lung function.
    Eur Respir J. 2019 Dec 20. pii: 13993003.01692-2019.
    PubMed     Abstract available


  65. RUESEN C, Chaidir L, Ugarte-Gil C, van Ingen J, et al
    Diabetes is associated with genotypically drug-resistant tuberculosis.
    Eur Respir J. 2019 Dec 12. pii: 13993003.01891-2019.
    PubMed    


  66. BOMANJI J, Sharma R, Mittal BR, Gambhir S, et al
    PET/CT features of Extrapulmonary Tuberculosis at first clinical presentation - a cross-sectional observational (18)F-FDG imaging study across six countries.
    Eur Respir J. 2019 Dec 12. pii: 13993003.01959-2019.
    PubMed     Abstract available


  67. GENESTET C, Paret R, Pichat C, Berland JL, et al
    Routine survey of Mycobacterium tuberculosis isolates reveals nosocomial transmission.
    Eur Respir J. 2019 Dec 5. pii: 13993003.01888-2019.
    PubMed    


  68. LEE SW, Kang YA, Jin CE, Kim HC, et al
    Gene-based diagnosis of tuberculosis with a new-generation pathogen enrichment technique.
    Eur Respir J. 2019 Dec 5. pii: 13993003.01885-2019.
    PubMed    


    November 2019
  69. KERKHOFF AD, Sossen B, Schutz C, Reipold EI, et al
    Diagnostic sensitivity of SILVAMP TB-LAM (FujiLAM) point-of-care urine assay for extra-pulmonary tuberculosis in people living with HIV.
    Eur Respir J. 2019 Nov 7. pii: 13993003.01259-2019.
    PubMed    


    October 2019
  70. OLAYANJU O, Esmail A, Limberis J, Dheda K, et al
    A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug resistant tuberculosis.
    Eur Respir J. 2019 Oct 16. pii: 13993003.01181-2019.
    PubMed     Abstract available


  71. BORISOV S, Danila E, Maryandyshev A, Dalcolmo M, et al
    Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report.
    Eur Respir J. 2019 Oct 10. pii: 13993003.01522-2019.
    PubMed     Abstract available


  72. DIEL R, Schluger NW
    Is adding fluoroquinolones to regimens for treating isoniazid-resistant tuberculosis necessary?
    Eur Respir J. 2019;54.
    PubMed    


  73. CAMINERO JA, Garcia-Basteiro AL, Rendon A, Piubello A, et al
    The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines.
    Eur Respir J. 2019;54.
    PubMed    


  74. ZELLWEGER JP
    Screening migrants for tuberculosis and latent TB infection: the reward will come later.
    Eur Respir J. 2019;54.
    PubMed    


    September 2019
  75. AHMAD BB, Kristensen KL, Glenthoj JP, Poulsen A, et al
    Latent tuberculosis infection among minor asylum seekers in Denmark.
    Eur Respir J. 2019 Sep 26. pii: 13993003.01688-2019.
    PubMed    


  76. EL ACHKAR S, Demanche C, Osman M, Rafei R, et al
    Zoonotic tuberculosis in humans assessed by next-generation sequencing: an 18-month nationwide study in Lebanon.
    Eur Respir J. 2019 Sep 26. pii: 13993003.00513-2019.
    PubMed    


  77. SPRUIJT I, Tesfay Haile D, Suurmond J, van den Hof S, et al
    Latent tuberculosis screening and treatment among asylum seekers: a mixed methods study.
    Eur Respir J. 2019 Sep 19. pii: 13993003.00861-2019.
    PubMed     Abstract available


  78. GAFAR F, Van't Boveneind-Vrubleuskaya N, Akkerman OW, Wilffert B, et al
    Nationwide analysis of treatment outcomes in children and adolescents routinely treated for tuberculosis in The Netherlands.
    Eur Respir J. 2019 Sep 12. pii: 13993003.01402-2019.
    PubMed     Abstract available


  79. SOTGIU G, Goletti D, Matteelli A
    Global tuberculosis prevention: should we start from the beginning?
    Eur Respir J. 2019;54.
    PubMed    


  80. REEVE BWP, Centis R, Theron G
    Still dying in plain sight: missed and misclassified deaths due to tuberculosis in hospitals.
    Eur Respir J. 2019;54.
    PubMed    


    August 2019
  81. DIEL R, Kohl TA, Mauer F, Merker M, et al
    Accuracy of whole genome sequencing to determine recent tuberculosis transmission: an 11-year population-based study in Hamburg, Germany.
    Eur Respir J. 2019 Aug 29. pii: 13993003.01154-2019.
    PubMed    


  82. VILLA S, Codecasa LR, Faccini M, Pontello MM, et al
    Tuberculosis among asylum-seekers in Milan, Italy: Epidemiological analysis and evaluation of interventions.
    Eur Respir J. 2019 Aug 14. pii: 13993003.00896-2019.
    PubMed     Abstract available


    July 2019
  83. GARCIA-BASTEIRO AL, Hurtado JC, Castillo P, Fernandes F, et al
    Unmasking the hidden tuberculosis mortality burden in a large postmortem study in Maputo Central Hospital, Mozambique.
    Eur Respir J. 2019 Jul 25. pii: 13993003.00312-2019.
    PubMed     Abstract available


    June 2019
  84. GUPTA RK, Rosenberg G, Eriksen J, Lipman M, et al
    Tuberculosis following Renal Transplantation in England, Wales and Northern Ireland: A National Registry-based Cohort Study.
    Eur Respir J. 2019 Jun 27. pii: 13993003.02245-2018.
    PubMed    


  85. COHEN A, Mathiasen VD, Schon T, Wejse C, et al
    The global prevalence of latent tuberculosis: a systematic review and meta-analysis.
    Eur Respir J. 2019 Jun 20. pii: 13993003.00655-2019.
    PubMed     Abstract available


  86. MELSEW YA, Cheng AC, McBryde ES, Denholm JT, et al
    Profiles of tuberculosis disease activation among contacts of patients with tuberculosis.
    Eur Respir J. 2019 Jun 4. pii: 13993003.00353-2019.
    PubMed    


  87. SNOW KJ, Sawyer SM, Denholm JT, Graham SM, et al
    Explaining variation in the burden of child and adolescent tuberculosis.
    Eur Respir J. 2019;53.
    PubMed    


    May 2019
  88. POORAN A, Davids M, Nel A, Shoko A, et al
    IL-4 subverts mycobacterial containment in M. tuberculosis-infected human macrophages.
    Eur Respir J. 2019 May 16. pii: 13993003.02242-2018.
    PubMed     Abstract available


  89. VASILYEVA I, Mariandyshev A, Kazennyy B, Davidaviciene E, et al
    Early access of bedaquiline for extensively drug-resistant (XDR) and pre-XDR tuberculosis.
    Eur Respir J. 2019 May 16. pii: 13993003.02208-2018.
    PubMed    


  90. WALKER IF, Shi O, Hicks J, Elsey H, et al
    Analysis of loss to follow up in 4,099 multidrug-resistant pulmonary tuberculosis patients.
    Eur Respir J. 2019 May 9. pii: 13993003.00353-2018.
    PubMed     Abstract available


  91. DEKKERS BGJ, Bolhuis MS, Ter Beek L, de Lange WCM, et al
    Reduced moxifloxacin exposure in patients with tuberculosis and diabetes.
    Eur Respir J. 2019 May 2. pii: 13993003.00373-2019.
    PubMed    


  92. MARTINEZ L, Verma R, Croda J, Horsburgh CR, et al
    Detection, survival and infectious potential of Mycobacterium tuberculosis in the environment: A review of the evidence and epidemiological implications.
    Eur Respir J. 2019 May 2. pii: 13993003.02302-2018.
    PubMed     Abstract available


  93. CHEN YY, Pan SW, Shen HS, Chuang FY, et al
    Declining trend in incidence of tuberculosis in adolescents and young adults in Taiwan.
    Eur Respir J. 2019;53.
    PubMed    


    April 2019
  94. MIGLIORI GB, Nardell E, Yedilbayev A, D'Ambrosio L, et al
    Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe.
    Eur Respir J. 2019 Apr 25. pii: 13993003.00391-2019.
    PubMed     Abstract available


  95. FURIN J, Sotgiu G
    Protecting those who serve: are we doing enough to prevent tuberculosis in healthcare workers?
    Eur Respir J. 2019;53.
    PubMed    


    March 2019
  96. LANCIONI C, Swarbrick GM, Park B, Nyendak M, et al
    Recognition of CD8(+) T cell Epitopes to Identify Adults with Pulmonary Tuberculosis.
    Eur Respir J. 2019 Mar 28. pii: 13993003.02053-2018.
    PubMed    


  97. VISCA D, Zampogna E, Sotgiu G, Centis R, et al
    Pulmonary rehabilitation is effective in patients with tuberculosis pulmonary sequelae.
    Eur Respir J. 2019;53.
    PubMed    


  98. GEBRESELASSIE N, Falzon D, Zignol M, Kasaeva T, et al
    Tuberculosis research questions identified through the WHO policy guideline development process.
    Eur Respir J. 2019;53.
    PubMed    


  99. CHAN PC, Lee PH, Lu MJ, Huang YC, et al
    Tolerability of rifapentine-based regimens in latent tuberculosis infection treatment in the elderly.
    Eur Respir J. 2019;53.
    PubMed    


    February 2019
  100. APRIANI L, McAllister S, Sharples K, Alisjahbana B, et al
    Latent tuberculosis infection in health care workers in low and middle-income countries: an updated systematic review.
    Eur Respir J. 2019 Feb 20. pii: 13993003.01789-2018.
    PubMed     Abstract available


  101. JOLLIFFE DA, Ganmaa D, Wejse C, Raqib R, et al
    Adjunctive vitamin D in tuberculosis treatment: meta-analysis of individual participant data.
    Eur Respir J. 2019 Feb 6. pii: 13993003.02003-2018.
    PubMed     Abstract available


    January 2019
  102. PAGE ID, Byanyima R, Hosmane S, Onyachi N, et al
    Chronic pulmonary aspergillosis commonly complicates treated pulmonary tuberculosis with residual cavitation.
    Eur Respir J. 2019 Jan 31. pii: 13993003.01184-2018.
    PubMed     Abstract available


  103. VAN LETH F, Brinkmann F, Cirillo DM, Dheda K, et al
    The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation.
    Eur Respir J. 2019;53.
    PubMed    


  104. ABUBAKAR I, Lipman M
    Reducing loss to follow-up during treatment for drug-resistant tuberculosis.
    Eur Respir J. 2019;53.
    PubMed    


  105. ROSALES-KLINTZ S, Bruchfeld J, Haas W, Heldal E, et al
    Guidance for programmatic management of latent tuberculosis infection in the European Union/European Economic Area.
    Eur Respir J. 2019;53.
    PubMed    


    December 2018
  106. MENZIES D, Trajman A
    New short regimens for latent tuberculosis treatment: safety first!
    Eur Respir J. 2018;52.
    PubMed    


    November 2018
  107. FROBERG G, Jansson L, Bruchfeld J
    Treatment of latent tuberculosis with 12-weeks isoniazid/rifapentine in clinical practice.
    Eur Respir J. 2018 Nov 8. pii: 13993003.01128-2018.
    PubMed    


    October 2018
  108. DALE KD, Trauer JM, Dodd PJ, Houben RMGJ, et al
    Estimating the prevalence of latent tuberculosis in a low incidence setting: Australia.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01218-2018.
    PubMed     Abstract available


  109. NDJEKA N, Schnippel K, Master I, Meintjes G, et al
    High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01528-2018.
    PubMed     Abstract available


  110. GOLETTI D, Lindestam Arlehamn CS, Scriba TJ, Anthony R, et al
    Can we predict tuberculosis cure? Current tools available.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01089-2018.
    PubMed     Abstract available


  111. GAO L, Zhang H, Xin H, Liu J, et al
    Short-course Regimens of Rifapentine plus Isoniazid to Treat Latent Tuberculosis Infection in Older Chinese: a Randomised Controlled Study.
    Eur Respir J. 2018 Oct 25. pii: 13993003.01470-2018.
    PubMed     Abstract available


  112. COLLIN SM, de Vries G, Lonnroth K, Migliori GB, et al
    Tuberculosis in the European Union and European Economic Area: a survey of national tuberculosis programmes.
    Eur Respir J. 2018 Oct 11. pii: 13993003.01449-2018.
    PubMed     Abstract available


  113. LAW S, Daftary A, O'Donnell M, Padayatchi N, et al
    Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review.
    Eur Respir J. 2018 Oct 11. pii: 13993003.01030-2018.
    PubMed     Abstract available


  114. GANDHI NR, Brust JCM, Shah NS
    A new era for treatment of drug-resistant tuberculosis.
    Eur Respir J. 2018;52.
    PubMed    


  115. RUHWALD M, Diel R
    Escaping the Plato's cave of latent tuberculosis testing: a path for developers of predictive tests for risk of tuberculosis.
    Eur Respir J. 2018;52.
    PubMed    


    September 2018
  116. MIGLIORI GB, Sotgiu G, Rosales-Klintz S, van der Werf MJ, et al
    European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following publication of the new World Health Organization recommendations.
    Eur Respir J. 2018 Sep 12. pii: 13993003.01617-2018.
    PubMed    


  117. CABIBBE AM, Walker TM, Niemann S, Cirillo DM, et al
    Whole Genome Sequencing of Mycobacterium tuberculosis.
    Eur Respir J. 2018 Sep 12. pii: 13993003.01163-2018.
    PubMed     Abstract available


    August 2018
  118. NSENGIYUMVA NP, Mappin-Kasirer B, Oxlade O, Bastos M, et al
    Evaluating the potential costs and impact of digital health technologies for tuberculosis treatment support.
    Eur Respir J. 2018 Aug 30. pii: 13993003.01363-2018.
    PubMed     Abstract available


  119. KIK SV, Schumacher S, Maria Cirillo D, Churchyard G, et al
    An evaluation framework for new tests that predict progression from tuberculosis infection to clinical disease.
    Eur Respir J. 2018 Aug 23. pii: 13993003.00946-2018.
    PubMed     Abstract available


  120. AULD SC, Sarita Shah N, Mathema B, Brown TS, et al
    XDR tuberculosis in South Africa: genomic evidence supporting transmission in communities.
    Eur Respir J. 2018 Aug 16. pii: 13993003.00246-2018.
    PubMed     Abstract available


  121. UZORKA JW, Delfos NM, Witte AMC, Scheper H, et al
    Tuberculosis after a borderline QuantiFERON result during screening before infliximab.
    Eur Respir J. 2018;52.
    PubMed    


    June 2018
  122. PONTALI E, Sotgiu G, Tiberi S, Tadolini M, et al
    Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Eur Respir J. 2018 Jun 14. pii: 13993003.00934-2018.
    PubMed    


  123. GUGLIELMETTI L, Tiberi S, Burman M, Kunst H, et al
    QT prolongation and cardiac toxicity of new tuberculosis drugs in Europe: A Tuberculosis Network European Trialsgroup (TBnet) study.
    Eur Respir J. 2018 Jun 7. pii: 13993003.00537-2018.
    PubMed    


    May 2018
  124. DOBLER CC, Fox GJ, Douglas P, Viney KA, et al
    Screening for tuberculosis in migrants and visitors from high incidence settings: present and future perspectives.
    Eur Respir J. 2018 May 24. pii: 13993003.00591-2018.
    PubMed     Abstract available


  125. ASSEFA Y, Assefa Y, Woldeyohannes S, Hamada Y, et al
    Three-month daily Rifampicin and Isoniazid compared to six or nine-month Isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
    Eur Respir J. 2018 May 10. pii: 13993003.00395-2018.
    PubMed    


  126. MOHR E, Hughes J, Reuter A, Trivino Duran L, et al
    Delamanid for Rifampicin-Resistant Tuberculosis: A Retrospective Study from South Africa.
    Eur Respir J. 2018 May 3. pii: 13993003.00017-2018.
    PubMed     Abstract available


  127. MUSTAZZOLU A, Borroni E, Maria Cirillo D, Giannoni F, et al
    Trend of rifampicin resistant, MDR and XDR tuberculosis in Italy, 2009-2016.
    Eur Respir J. 2018 May 3. pii: 13993003.00070-2018.
    PubMed    


  128. ABUBAKAR I, Matteelli A, de Vries G, Zenner D, et al
    Towards tackling tuberculosis in vulnerable groups in the European Union: the E-DETECT TB consortium.
    Eur Respir J. 2018;51.
    PubMed    


  129. VILLANUEVA P, Neth O, Ritz N, Tebruegge M, et al
    Use of Xpert MTB/RIF Ultra assays among paediatric tuberculosis experts in Europe.
    Eur Respir J. 2018;51.
    PubMed    



  130. "Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey." Dodge R. Lim, Anna S. Dean, Mary Rosary Taguinod-Santiago, Angeli Borbe-Reyes, Andrea Maurizio Cabibbe, Matteo Zignol, Ra
    Eur Respir J. 2018;51.
    PubMed    


    April 2018
  131. OLAYANJU O, Limberis J, Esmail A, Oelofse S, et al
    LONG TERM BEDAQUILINE-RELATED TREATMENT OUTCOMES IN PATIENTS WITH EXTENSIVELY DRUG RESISTANT TUBERCULOSIS FROM SOUTH AFRICA.
    Eur Respir J. 2018 Apr 26. pii: 13993003.00544-2018.
    PubMed    


  132. MIGLIORI GB, Sotgiu G, Rosales-Klintz S, Centis R, et al
    ERS/ECDC Statement: European Union Standards for Tuberculosis Care - 2017 update.
    Eur Respir J. 2018 Apr 20. pii: 13993003.02678-2017.
    PubMed     Abstract available


  133. CABIBBE AM, Trovato A, De Filippo MR, Ghodousi A, et al
    Countrywide implementation of whole genome sequencing: an opportunity to improve tuberculosis management, surveillance and contact tracing in low incidence countries.
    Eur Respir J. 2018 Apr 12. pii: 13993003.00387-2018.
    PubMed    


  134. CHANG KC, Chung-Ching Leung E, Law WS, Leung WM, et al
    Early experience with delamanid-containing regimens in the treatment of complicated multidrug-resistant tuberculosis in Hong Kong.
    Eur Respir J. 2018 Apr 12. pii: 13993003.00159-2018.
    PubMed    


    March 2018
  135. LYLES G, Ogarkov O, Zhdanova S, Peloquin CA, et al
    Pharmacokinetics of tuberculosis drugs in HIV infected patients from Irkutsk, Russian Federation: redefining drug activity.
    Eur Respir J. 2018 Mar 29. pii: 13993003.00109-2018.
    PubMed    


  136. JAFARI C, Olaru ID, Daduna F, Ernst M, et al
    Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods.
    Eur Respir J. 2018 Mar 29. pii: 13993003.02189-2017.
    PubMed     Abstract available


  137. LIM DR, Dean AS, Taguinod-Santiago MR, Borbe-Reyes A, et al
    Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey.
    Eur Respir J. 2018 Mar 1. pii: 13993003.02571-2017.
    PubMed    


  138. KIM CT, Kim TO, Shin HJ, Ko YC, et al
    Bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis: a multicentre cohort study in Korea.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  139. SAUNDERS MJ, Tovar MA, Datta S, Evans BEW, et al
    Pragmatic tuberculosis prevention policies for primary care in low- and middle-income countries.
    Eur Respir J. 2018;51.
    PubMed    


  140. RUDGARD WE, das Chagas NS, Gayoso R, Barreto ML, et al
    Uptake of governmental social protection and financial hardship during drug-resistant tuberculosis treatment in Rio de Janeiro, Brazil.
    Eur Respir J. 2018;51.
    PubMed    


  141. MUSVOSVI M, Duffy D, Filander E, Africa H, et al
    T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation.
    Eur Respir J. 2018;51.
    PubMed    


  142. GILPIN C, Korobitsyn A, Migliori GB, Raviglione MC, et al
    The World Health Organization standards for tuberculosis care and management.
    Eur Respir J. 2018;51.
    PubMed    


  143. DE VRIES G, van den Hof S, Op de Coul E, van Crevel R, et al
    Closing the gap in surveillance of tuberculosis and HIV co-infection, and the need for clinician-public health alliances.
    Eur Respir J. 2018;51.
    PubMed    


  144. MUNOZ-TORRICO M, Salazar MA, Millan MJM, Martinez Orozco JA, et al
    Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.
    Eur Respir J. 2018;51.
    PubMed    


  145. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Renal Fanconi syndrome with meropenem-containing regimen in drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed    


  146. HALLEUX CM, Falzon D, Merle C, Jaramillo E, et al
    The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed    


    February 2018
  147. SULIS G, Agliati A, Pinsi G, Bozzola G, et al
    Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting.
    Eur Respir J. 2018 Feb 8. pii: 13993003.02345-2017.
    PubMed    


  148. AKKERMAN OW, Grasmeijer F, de Lange WCM, Kerstjens HAM, et al
    Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis.
    Eur Respir J. 2018 Feb 1. pii: 13993003.02490-2017.
    PubMed    


  149. CHIANG CY, Trebucq A
    Tuberculosis re-treatment after exclusion of rifampicin resistance.
    Eur Respir J. 2018;51.
    PubMed    


  150. KEMPKER RR, Heinrichs MT, Nikolaishvili K, Sabulua I, et al
    A comparison of linezolid lung tissue concentrations among patients with drug-resistant tuberculosis.
    Eur Respir J. 2018;51.
    PubMed    


  151. JOHNSTON JC, van der Kop ML, Smillie K, Ogilvie G, et al
    The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  152. GARCIA-BASTEIRO AL, Schaaf HS, Diel R, Migliori GB, et al
    Adolescents and young adults: a neglected population group for tuberculosis surveillance.
    Eur Respir J. 2018;51.
    PubMed    


  153. ALVAREZ-URIA G, Midde M
    Sex differences and factors influencing the duration of the QT interval in patients on anti-tuberculosis therapy.
    Eur Respir J. 2018;51.
    PubMed    


  154. SNOW KJ, Sismanidis C, Denholm J, Sawyer SM, et al
    The incidence of tuberculosis among adolescents and young adults: a global estimate.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  155. HEYCKENDORF J, van Leth F, Kalsdorf B, Olaru ID, et al
    Relapse-free cure from multidrug-resistant tuberculosis in Germany.
    Eur Respir J. 2018;51.
    PubMed    


  156. CHIANG CY, Trebucq A, Piubello A, Rieder HL, et al
    Should gatifloxacin be included in the model list of essential medicines?
    Eur Respir J. 2018;51.
    PubMed    


    January 2018
  157. HEYSELL SK, Ahmed S, Rahman MT, Akhanda MW, et al
    Hearing loss with Kanamycin treatment for multidrug-resistant tuberculosis in Bangladesh.
    Eur Respir J. 2018 Jan 18. pii: 13993003.01778-2017.
    PubMed    


  158. ACUNA-VILLAORDUNA C, Jones-Lopez EC, Fregona G, Marques-Rodrigues P, et al
    Intensity of exposure to pulmonary tuberculosis determines risk of tuberculosis infection and disease.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  159. NGWATU BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, et al
    The impact of digital health technologies on tuberculosis treatment: a systematic review.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  160. LOUTET MG, Burman M, Jayasekera N, Trathen D, et al
    National roll-out of latent tuberculosis testing and treatment for new migrants in England: a retrospective evaluation in a high-incidence area.
    Eur Respir J. 2018;51.
    PubMed     Abstract available


  161. AL YAQUOBI F, Al-Abri S, Al-Abri B, Al-Abaidani I, et al
    Tuberculosis elimination: a dream or a reality? The case of Oman.
    Eur Respir J. 2018;51.
    PubMed    


  162. VAN DEN ELSEN SHJ, Akkerman OW, Huisman JR, Touw DJ, et al
    Lack of penetration of amikacin into saliva of tuberculosis patients.
    Eur Respir J. 2018;51.
    PubMed    


  163. PADRAO E, Oliveira O, Felgueiras O, Gaio AR, et al
    Tuberculosis and tobacco: is there any epidemiological association?
    Eur Respir J. 2018;51.
    PubMed    


    December 2017
  164. CHE Y, Song Q, Yang T, Ping G, et al
    Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use.
    Eur Respir J. 2017;50.
    PubMed    


  165. CABIBBE AM, Sotgiu G, Izco S, Migliori GB, et al
    Genotypic and phenotypic M. tuberculosis resistance: guiding clinicians to prescribe the correct regimens.
    Eur Respir J. 2017;50.
    PubMed    


  166. ABADIE ME, Strich JR, Kim T, Xie YL, et al
    Renal Fanconi syndrome with meropenem/amoxicillin-clavulanate during treatment of extensively drug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed    


  167. MIOTTO P, Tessema B, Tagliani E, Chindelevitch L, et al
    A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


    November 2017
  168. LUZZATI R, Migliori GB, Zignol M, Cirillo DM, et al
    Children under 5 years are at risk for tuberculosis after occasional contact with highly contagious patients: outbreak from a smear-positive healthcare worker.
    Eur Respir J. 2017;50.
    PubMed    


  169. FALZON D, Migliori GB, Jaramillo E, Weyer K, et al
    Digital health to end tuberculosis in the Sustainable Development Goals era: achievements, evidence and future perspectives.
    Eur Respir J. 2017;50.
    PubMed    


  170. FURIN J, Lessem E, Cox V
    Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis.
    Eur Respir J. 2017;50.
    PubMed    


  171. KUKSA L, Barkane L, Hittel N, Gupta R, et al
    Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.
    Eur Respir J. 2017;50.
    PubMed    


  172. VAN DER WERF MJ, Sotgiu G, Dara M
    Closing the gap in surveillance of tuberculosis and HIV co-infection: a European perspective on the need for clinician-public health alliances.
    Eur Respir J. 2017;50.
    PubMed    


  173. ARNOLDUSSEN M, Schimmel H, Op de Coul E, van den Hof S, et al
    Tuberculosis patients with unknown HIV status in the Netherlands: analysing underreporting and lack of testing.
    Eur Respir J. 2017;50.
    PubMed    


    October 2017
  174. VAN DE BERG S, Erkens C, van Rest J, van den Hof S, et al
    Evaluation of tuberculosis screening of immigrants in the Netherlands.
    Eur Respir J. 2017;50.
    PubMed    


  175. HELDAL E
    A katG 315 mutation alone should not lead to exclusion of isoniazid in treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;50.
    PubMed    


  176. CHESOV D, Ciobanu N, Lange C, Heyckendorf J, et al
    High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova.
    Eur Respir J. 2017;50.
    PubMed    


  177. KODAMA C, Lange B, Olaru ID, Khan P, et al
    Mycobacterium tuberculosis transmission from patients with drug-resistant compared to drug-susceptible TB: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed    


  178. FIEBIG L, Hauer B, Andres M, Haas W, et al
    Tuberculosis screening in asylum seekers in Germany, 2015: characteristics of cases and yield.
    Eur Respir J. 2017;50.
    PubMed    


    September 2017
  179. FOURNIER A, Bernard C, Sougakoff W, Quelet S, et al
    Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission.
    Eur Respir J. 2017;50.
    PubMed    


    August 2017
  180. CHEE CBE, KhinMar KW, Sng LH, Jureen R, et al
    The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible?
    Eur Respir J. 2017;50.
    PubMed    


  181. CAZABON D, Suresh A, Oghor C, Qin ZZ, et al
    Implementation of Xpert MTB/RIF in 22 high tuberculosis burden countries: are we making progress?
    Eur Respir J. 2017;50.
    PubMed    


  182. LEE MR, Ho CM, Lee CH, Lee MC, et al
    Tuberculosis contact investigation in an intermediate burden setting: implications from a large tuberculosis contact cohort in Taiwan.
    Eur Respir J. 2017;50.
    PubMed    


  183. DOBLER CC, Cheung K, Nguyen J, Martin A, et al
    Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


    July 2017
  184. CAMINERO JA, Piubello A, Scardigli A, Migliori GB, et al
    Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases.
    Eur Respir J. 2017;50.
    PubMed    


  185. AHMAD KHAN F, Pande T, Tessema B, Song R, et al
    Computer-aided reading of tuberculosis chest radiography: moving the research agenda forward to inform policy.
    Eur Respir J. 2017;50.
    PubMed    


  186. RAVIGLIONE M, Poznyak V
    Targeting harmful use of alcohol for prevention and treatment of tuberculosis: a call for action.
    Eur Respir J. 2017;50.
    PubMed    


  187. IMTIAZ S, Shield KD, Roerecke M, Samokhvalov AV, et al
    Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  188. AHMAD KHAN F, Salim MAH, du Cros P, Casas EC, et al
    Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  189. ZENNER D, Loutet MG, Harris R, Wilson S, et al
    Evaluating 17 years of latent tuberculosis infection screening in north-west England: a retrospective cohort study of reactivation.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  190. GUGLIELMETTI L, Varaine F, Huerga H, Bonnet M, et al
    Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance.
    Eur Respir J. 2017;50.
    PubMed    


  191. ONI T, Berkowitz N, Kubjane M, Goliath R, et al
    Trilateral overlap of tuberculosis, diabetes and HIV-1 in a high-burden African setting: implications for TB control.
    Eur Respir J. 2017;50.
    PubMed     Abstract available


  192. MULLERPATTAN JB, Nikam C, Sharma U, Rodrigues C, et al
    Rifampicin-resistant tuberculosis: what is the best initial empiric regimen in Mumbai, India?
    Eur Respir J. 2017;50.
    PubMed    


    June 2017
  193. SOLOVIC I, Abubakar I, Sotgiu G, Dara M, et al
    Standard operating procedures for tuberculosis care.
    Eur Respir J. 2017;49.
    PubMed    


  194. VAN DER WERF MJ, Kodmon C, Catchpole M
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed    


  195. HELDAL E, Van Deun A, Chiang CY, Rieder HL, et al
    Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe.
    Eur Respir J. 2017;49.
    PubMed    


  196. VAN DEUN A, Chiang CY
    Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance.
    Eur Respir J. 2017;49.
    PubMed    


  197. BOERE TM, Visser DH, van Furth AM, Lips P, et al
    Solar ultraviolet B exposure and global variation in tuberculosis incidence: an ecological analysis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    May 2017
  198. OLARU ID, Heyckendorf J, Andres S, Kalsdorf B, et al
    Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  199. GUGLIELMETTI L
    Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity?
    Eur Respir J. 2017;49.
    PubMed    


  200. MILLER C, Lonnroth K, Sotgiu G, Migliori GB, et al
    The long and winding road of chest radiography for tuberculosis detection.
    Eur Respir J. 2017;49.
    PubMed    


  201. RAHMAN MT, Codlin AJ, Rahman MM, Nahar A, et al
    An evaluation of automated chest radiography reading software for tuberculosis screening among public- and private-sector patients.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    April 2017
  202. CATANZARO DG, Trollip AP, Seifert M, Georghiou SB, et al
    Evaluation of the microscopic observation drug susceptibility assay for the detection of first- and second-line drug susceptibility for Mycobacterium tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  203. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Resistance profile of drugs composing the "shorter" regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015.
    Eur Respir J. 2017;49.
    PubMed    


  204. NAKIWALA D, Kellgren L, Herzmann C, Olaru ID, et al
    Language discordance between tuberculosis patients and healthcare providers challenging universal access.
    Eur Respir J. 2017;49.
    PubMed    


  205. BOZORGMEHR K, Joggerst B, Wagner U, Stock C, et al
    Yield of tuberculosis screening in asylum-seekers by country of origin: analysis of screening data in a German federal state (2002-2015).
    Eur Respir J. 2017;49.
    PubMed    


  206. FALZON D, Jaramillo E, Gilpin C, Weyer K, et al
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  207. DAVIES FORSMAN L, Bruchfeld J, Alffenaar JC
    Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


    March 2017
  208. PONTALI E, D'Ambrosio L, Centis R, Sotgiu G, et al
    Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Eur Respir J. 2017;49.
    PubMed    


  209. YASSIN MA, Jaramillo E, Wandwalo E, Falzon D, et al
    Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated.
    Eur Respir J. 2017;49.
    PubMed    


  210. DALCOLMO M, Gayoso R, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  211. FALZON D, Schunemann HJ, Harausz E, Gonzalez-Angulo L, et al
    World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  212. SINKOU H, Hurevich H, Rusovich V, Zhylevich L, et al
    Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience.
    Eur Respir J. 2017;49.
    PubMed    


  213. VAN DER WERF MJ, Hollo V, Kodmon C, Dara M, et al
    Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union.
    Eur Respir J. 2017;49.
    PubMed    


  214. KAMADA A, Amishima M
    QuantiFERON-TB(R) Gold Plus as a potential tuberculosis treatment monitoring tool.
    Eur Respir J. 2017;49.
    PubMed    


  215. BJORN-MORTENSEN K, Lillebaek T, Koch A, Soborg B, et al
    Extent of transmission captured by contact tracing in a tuberculosis high endemic setting.
    Eur Respir J. 2017;49.
    PubMed    


  216. VAN KAMPENHOUT E, Bolhuis MS, Alffenaar JC, Oswald LM, et al
    Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  217. UDWADIA ZF, Ganatra S, Mullerpattan JB
    Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India.
    Eur Respir J. 2017;49.
    PubMed    


  218. GARCIA-BASTEIRO AL, Miranda Ribeiro R, Brew J, Sacoor C, et al
    Tuberculosis on the rise in southern Mozambique (1997-2012).
    Eur Respir J. 2017;49.
    PubMed    


  219. VAN DER PAARDT AL, Akkerman OW, Gualano G, Palmieri F, et al
    Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed    


  220. LU P, Liu Q, Martinez L, Yang H, et al
    Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China.
    Eur Respir J. 2017;49.
    PubMed    


  221. ROTH DZ, Ronald LA, Ling D, Chiang LY, et al
    Impact of interferon-gamma release assay on the latent tuberculosis cascade of care: a population-based study.
    Eur Respir J. 2017;49.
    PubMed    


  222. BASTOS ML, Lan Z, Menzies D
    An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


    February 2017
  223. BLASI F, Matteelli A, Sotgiu G, Cirillo DM, et al
    Moving towards tuberculosis elimination: a call for action from Italy and a possible model for other low tuberculosis incidence countries.
    Eur Respir J. 2017;49.
    PubMed    


    January 2017
  224. SOTGIU G, Migliori GB
    Group 5 drugs for multidrug-resistant tuberculosis: is the glass half full or half empty?
    Eur Respir J. 2017;49.
    PubMed    


  225. JAVAID A, Ahmad N, Khan AH, Shaheen Z, et al
    Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country.
    Eur Respir J. 2017;49.
    PubMed    


  226. FOX GJ, Benedetti A, Cox H, Koh WJ, et al
    Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available


  227. IZCO S, Eyene J, Perez-Lago L, Herranz M, et al
    Equatorial Guinea, a multidrug-resistant tuberculosis hotspot in Central Africa.
    Eur Respir J. 2017;49.
    PubMed    


  228. FRANCISCO J, Oliveira O, Felgueiras O, Gaio AR, et al
    How much is too much alcohol in tuberculosis?
    Eur Respir J. 2017;49.
    PubMed    


  229. NATHAVITHARANA RR, Cudahy PG, Schumacher SG, Steingart KR, et al
    Accuracy of line probe assays for the diagnosis of pulmonary and multidrug-resistant tuberculosis: a systematic review and meta-analysis.
    Eur Respir J. 2017;49.
    PubMed     Abstract available



  230. "Monitoring latent tuberculosis infection diagnosis and management in the Netherlands." Connie G.M. Erkens, Erika Slump, Maurits Verhagen, Henrieke Schimmel, Gerard de Vries, Frank Cobelens and Susan van den Hof. Eur Respir J 2016; 47: 1492-1501.
    Eur Respir J. 2017;49.
    PubMed    


  231. LIENHARDT C, Nahid P, Rich ML, Bansbach C, et al
    Target regimen profiles for treatment of tuberculosis: a WHO document.
    Eur Respir J. 2017;49.
    PubMed    


    December 2016
  232. PEDRAZZOLI D, Lalli M, Boccia D, Houben R, et al
    Can tuberculosis patients in resource-constrained settings afford chest radiography?
    Eur Respir J. 2016 Dec 23. pii: 1601877. doi: 10.1183/13993003.01877-2016.
    PubMed    


  233. GUGLIELMETTI L, Jaspard M, Le Du D, Lachatre M, et al
    Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis.
    Eur Respir J. 2016 Dec 22. pii: 1601799. doi: 10.1183/13993003.01799-2016.
    PubMed     Abstract available


  234. VEZIRIS N, Bernard C, Guglielmetti L, Le Du D, et al
    Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.
    Eur Respir J. 2016 Dec 22. pii: 1601719. doi: 10.1183/13993003.01719-2016.
    PubMed    


    November 2016
  235. PETRUCCIOLI E, Scriba TJ, Petrone L, Hatherill M, et al
    Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis.
    Eur Respir J. 2016 Nov 11. pii: ERJ-01012-2016. doi: 10.1183/13993003.01012-2016
    PubMed     Abstract available


  236. ALBERT H, Nathavitharana RR, Denkinger CM, Isaacs C, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1531-1532.
    PubMed    


  237. MASON PH, Oni T, van Herpen MM, Coussens AK, et al
    Tuberculosis prevention must integrate technological and basic care innovation.
    Eur Respir J. 2016;48:1529-1531.
    PubMed    


  238. TADOLINI M, Lingtsang RD, Tiberi S, Enwerem M, et al
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1527-1529.
    PubMed    


  239. WALLIS RS
    Cardiac safety of extensively drug-resistant tuberculosis regimens including bedaquiline, delamanid and clofazimine.
    Eur Respir J. 2016;48:1526-1527.
    PubMed    


  240. PILARSKI A, Penn N, Ratnakumar S, Barker RD, et al
    Variation in vitamin D deficiency among tuberculosis patients by ethnic group and geographical region of birth: evidence from a diverse south London population.
    Eur Respir J. 2016;48:1507-1510.
    PubMed    


  241. ERKENS CG, Slump E, Verhagen M, Schimmel H, et al
    Risk of developing tuberculosis disease among persons diagnosed with latent tuberculosis infection in the Netherlands.
    Eur Respir J. 2016;48:1420-1428.
    PubMed     Abstract available


  242. RENDON A, Fuentes Z, Torres-Duque CA, Granado MD, et al
    Roadmap for tuberculosis elimination in Latin American and Caribbean countries: a strategic alliance.
    Eur Respir J. 2016;48:1282-1287.
    PubMed    


  243. SOTGIU G, Beer N, Aliberti S, Migliori GB, et al
    Fighting tuberculosis in the EU/EEA: towards the new European Union standards on tuberculosis care.
    Eur Respir J. 2016;48:1278-1281.
    PubMed    


    October 2016
  244. UPLEKAR M, Atre S, Wells WA, Weil D, et al
    Mandatory tuberculosis case notification in high tuberculosis-incidence countries: policy and practice.
    Eur Respir J. 2016 Oct 20. pii: ERJ-00956-2016. doi: 10.1183/13993003.00956-2016
    PubMed     Abstract available


  245. VAN ALTENA R, Akkerman OW, Alffenaar JC, Kerstjens HA, et al
    Shorter treatment for multidrug-resistant tuberculosis: the good, the bad and the ugly.
    Eur Respir J. 2016 Oct 6. pii: ERJ-01208-2016. doi: 10.1183/13993003.01208-2016.
    PubMed    


  246. LEE RS, Proulx JF, Menzies D, Behr MA, et al
    Progression to tuberculosis disease increases with multiple exposures.
    Eur Respir J. 2016 Oct 6. pii: ERJ-00893-2016. doi: 10.1183/13993003.00893-2016.
    PubMed     Abstract available


  247. DE VRIES G, van Rest J, Meijer W, Schimmel H, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1255-1256.
    PubMed    


  248. ARRAZOLA DE ONATE W, Weber L, Janssens K, Wanlin M, et al
    Tuberculosis screening yield of asylum seekers in Europe.
    Eur Respir J. 2016;48:1253-1254.
    PubMed    


    September 2016
  249. WINGFIELD T, Tovar MA, Huff D, Boccia D, et al
    The economic effects of supporting tuberculosis-affected households in Peru.
    Eur Respir J. 2016 Sep 22. pii: ERJ-00066-2016. doi: 10.1183/13993003.00066-2016
    PubMed     Abstract available


    April 2016
  250. TIBERI S, Payen MC, Sotgiu G, D'Ambrosio L, et al
    Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.
    Eur Respir J. 2016;47:1235-43.
    PubMed     Abstract available


    March 2016
  251. KOLAHIAN S, Oz HH, Zhou B, Griessinger CM, et al
    The emerging role of myeloid-derived suppressor cells in lung diseases.
    Eur Respir J. 2016;47:967-77.
    PubMed     Abstract available


    January 2016
  252. BRIGDEN G, du Cros P, Wong S
    Barriers to new drug development in respiratory disease.
    Eur Respir J. 2016;47:356-7.
    PubMed    


  253. PINETON DE CHAMBRUN M, Lemiale V, Azoulay E
    Lung positron emission tomography with FDG in patients with haematological malignancies and acute respiratory failure.
    Eur Respir J. 2016;47:324-7.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Tuberculosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: